Bderlo 150mg Tablet

Some of the common side effects of the Bderlo 150mg Tablet are: Headache,
Fever
Loss of appetite
Pain in the eyes
Blurred vision
High blood pressure
Dry skin
lack of sleep.
Vomiting
Indigestion
Nausea
Reduced Kidney function, diarrhea, or constipation

Bderlo 150mg Tablet is not a drug used for selfmedication; it should always be taken as directed by a physician.As advised by the physician, it can be taken either with or without food.For best results in its effectiveness, the Bderlo 150mg Tablet must be swallowed rather than chewed, opened, or crushed. It is an oral drug that is given once daily, before meals, at the same time every day. The Bderlo 150mg Tablet should not be taken for at least three hours before or after food. Take it as prescribed by the physician.

The epidermal growth factor receptor (EGFR), a protein involved in the development and metastasis of cancer cells, is inhibited by Bderlo 150mg Tablet. EGFR plays a crucial role in cell division, growth, and survival of unregulated cells and contributes to the spread of disease. Bderlo 150mg Tablet inhibits EGFR activity, hence reducing or stopping the proliferation of cancer cells. It inhibits the cancer cells' signaling mechanisms.

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., & Albanell, J. (2022). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology, 20(21), 4292-4302.
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., & Baselga, J. (2023). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–non-small-cell lung cancer. Journal of Clinical Oncology, 21(12), 2237-2246.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., & Haber, D. A. (2024). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129-2139.
Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S.,  & Heigener, D. (2024). Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. Journal of Thoracic Oncology, 5(10), 1616-1622.
Wang Y, Schmid-Bindert G, Zhou C. (2025). Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol.